- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Using a Multinational Pediatric Cancer Registry Helps to Improve PFS in High-Risk Patients
May 29th 2020, 1:00am
The use of real-time comprehensive profiling provides valuable diagnostic information and identifies potential therapeutic targets in adults with malignancies, but this process remains widely underutilized for pediatric patients and represents a significant unmet need.
Avelumab Controls hCG Levels Lead to Remissions in Gestational Trophoblastic Tumors
May 29th 2020, 1:00am
Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.
Adjuvant Osimertinib Significantly Improves DFS in Early-Stage EGFR+ NSCLC
May 29th 2020, 1:00am
Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.
Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma
May 29th 2020, 1:00am
Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study.
Pembrolizumab Doubles PFS in Newly Diagnosed MSI-H/dMMR mCRC
May 29th 2020, 1:00am
Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.
Active Cancer Strongly Associated With Increased COVID-19 Mortality
May 29th 2020, 1:00am
An analysis of data collected in the COVID-19 and Cancer Consortium registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 compared with patients in remission or with no evidence of disease.
Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic Tumors
May 29th 2020, 1:00am
Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.
Dr. Powles on Maintenance Avelumab in Urothelial Carcinoma
May 29th 2020, 1:00am
Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.
Dr. Andre on Strategies to Improve Outcomes in Breast Cancer
May 28th 2020, 1:38am
Fabrice André, MD, PhD, discusses strategies to improve outcomes in patients with breast cancer.
Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast Cancer
May 28th 2020, 1:35am
Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC
May 27th 2020, 1:48am
The PARP inhibitor veliparib increased progression-free survival in women with hormone receptor-positive breast cancer and triple-negative breast cancer who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694).
Top Priorities Outlined in Next Decade of Breast Cancer Research
May 26th 2020, 11:40pm
Developing diagnostics to identify the molecular drivers of breast cancer and model the mechanisms of disease progression will be a key priority of the investigative efforts aimed at improving patient outcomes in the field over the next decade.
LSZ102 Shows Encouraging Activity in Combination With Ribociclib, Alpelisib in ER+ Breast Cancer
May 26th 2020, 5:25pm
LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.
Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets
May 24th 2020, 8:09pm
Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline.
Mindful Adaptation of Breast Cancer Treatment Necessary Amid COVID-19 Crisis
May 24th 2020, 7:36pm
Although little evidence exists with regard to how to best treat patients with breast cancer during the COVID-19 pandemic, guidelines have been issued by organizations like ESMO to assist providers with making those decisions.
Ipatasertib Survival Results Continue to Impress in TNBC
May 23rd 2020, 8:10pm
Adding ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival in patients with triple-negative breast cancer.
Dr. Park on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer
May 23rd 2020, 8:00pm
Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.
Dr. Dent on Final LOTUS Findings in TNBC
May 23rd 2020, 8:00pm
Rebecca Dent, MD, discusses the findings from the phase 2 LOTUS trial that treated patients with inoperable locally advanced/metastatic triple-negative breast cancer with first-line ipatasertib plus paclitaxel.
ASCO 2020: Oncology Experts Select Vital Studies Ahead of Virtual Meeting
May 21st 2020, 3:09pm
We spoke with leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their specialties.
ASCO 2020: Top KOLs Select Vital Studies Ahead of Virtual Meeting
May 21st 2020, 11:16am
Ahead of the 2020 ASCO Virtual Scientific Program, we spoke with a handful of leading oncologists in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and hematologic malignancies to gain their perspectives on the most significant studies in their respective specialties.